• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

PDGFRB Gene Record

  • Summary
  • Interactions
  • Claims
  • PDGFRB 5159 Druggable GenomeClinically Actionable

    Alternate Names:

    5159
    PLATELET DERIVED GROWTH FACTOR RECEPTOR BETA
    PDGFRB
    CD140B
    IBGC4
    IMF1
    JTK12
    KOGS
    PDGFR
    PDGFR-1
    PDGFR1
    PENTT
    173410
    8804
    ENSG00000113721
    OTTHUMG00000130053
    P09619
    PGFRB_HUMAN
    CD140 antigen-like family member B
    Platelet-derived growth factor receptor beta
    Beta platelet-derived growth factor receptor
    Beta-type platelet-derived growth factor receptor
    PDGFR-beta
    PDGF-R-beta
    CD_antigen=CD140b
    Platelet-derived growth factor receptor 1
    BETA PLATELET-DERIVED GROWTH FACTOR RECEPTOR PRECURSOR (EC 2.7.1.112) (PDGF-R-BETA) (CD140B ANTIGEN). [SOURCE:UNIPROT/SWISSPROT;ACC:P09619]
    4176
    PA33148
    T59102

    Gene Info:

    Target Subclass KInase
    Target Main Class Receptors
    Transmembrane Helix Count 1
    Target Subclass PDGFR
    Interpro Acc IPR001245
    Interpro Short Name Ser-Thr/Tyr_kinase_cat_dom
    Uniprot Evidence 1: Evidence at protein level
    Human Readable Name KINASE
    Interpro Name Serine-threonine/tyrosine-protein kinase catalytic domain
    Uniprot Status Swiss-Prot
    Human Readable Name DRUGGABLE GENOME
    Interpro Type Domain
    Target Class Receptors
    Target Subclass EC:2.7.10.1
    Gene Biotype PROTEIN_CODING
    (21 More Sources)

    Gene Categories: Category Details

    CELL SURFACE
    KINASE
    TYROSINE KINASE
    DRUGGABLE GENOME
    CLINICALLY ACTIONABLE

    Publications:

    Sonpavde et al., 2007, Pazopanib: a novel multitargeted tyrosine kinase inhibitor., Curr Oncol Rep
    Unnithan et al., 2007, The role of targeted therapy in metastatic renal cell carcinoma., ScientificWorldJournal
    Gollob, 2005, Sorafenib: scientific rationales for single-agent and combination therapy in clear-cell renal cell carcinoma., Clin Genitourin Cancer
    Guida et al., 2007, Sorafenib inhibits imatinib-resistant KIT and platelet-derived growth factor receptor beta gatekeeper mutants., Clin. Cancer Res.
    Gong L et al., 2017, PharmGKB summary: sorafenib pathways., Pharmacogenet Genomics
    David et al., 2007, Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders., Blood
    Sakurai Y et al., 2020, B-Cell Precursor-Acute Lymphoblastic Leukemia With EBF1-PDGFRB Fusion Treated With Hematopoietic Stem Cell Transplantation and Imatinib: A Case Report and Literature Review., J Pediatr Hematol Oncol
    Lengline E et al., 2013, Successful tyrosine kinase inhibitor therapy in a refractory B-cell precursor acute lymphoblastic leukemia with EBF1-PDGFRB fusion., Haematologica
    Weston et al., 2013, Tyrosine kinase inhibitor therapy induces remission in a patient with refractory EBF1-PDGFRB-positive acute lymphoblastic leukemia., J. Clin. Oncol.
    Jones et al., 2005, The development and application of imatinib., Expert Opin Drug Saf
    Modi et al., 2005, A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer., Breast Cancer Res. Treat.
    Johnson et al., 2005, Induction of heparin-binding EGF-like growth factor and activation of EGF receptor in imatinib mesylate-treated squamous carcinoma cells., J. Cell. Physiol.
    Basciani et al., 2005, Imatinib mesylate inhibits Leydig cell tumor growth: evidence for in vitro and in vivo activity., Cancer Res.
    Chen et al., 2006, The tyrosine kinase inhibitor imatinib fails to inhibit pancreatic cancer progression., Cancer Lett.
    Ishibashi T et al., 2016, Ph-like ALL-related novel fusion kinase ATF7IP-PDGFRB exhibits high sensitivity to tyrosine kinase inhibitors in murine cells., Exp Hematol
    Chen et al., 2006, Potent inhibition of platelet-derived growth factor-induced responses in vascular smooth muscle cells by BMS-354825 (dasatinib)., Mol. Pharmacol.
    Zhang et al., 2006, New assignments for multitasking signal transduction inhibitors., Mol. Pharmacol.
    Lindauer et al., 2010, Dasatinib., Recent Results Cancer Res.
    Zhang G et al., 2017, Acute Lymphoblastic Leukemia Patient with Variant ATF7IP/PDGFRB Fusion and Favorable Response to Tyrosine Kinase Inhibitor Treatment: A Case Report., Am J Case Rep
    Xiao W et al., 2018, A favorable outcome of advanced dermatofibrosarcoma protuberans under treatment with sunitinib after imatinib failure., Onco Targets Ther
    Pietras et al., 2005, A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer., J. Clin. Oncol.
    Barattè et al., 2004, Quantitation of SU1 1248, an oral multi-target tyrosine kinase inhibitor, and its metabolite in monkey tissues by liquid chromatograph with tandem mass spectrometry following semi-automated liquid-liquid extraction., J Chromatogr A
    Abrams et al., 2003, SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer., Mol. Cancer Ther.
    Mendel et al., 2003, In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship., Clin. Cancer Res.
    Quek R et al., 2009, Gastrointestinal stromal tumor: a clinical overview., Hematol Oncol Clin North Am
    Wind S et al., 2019, Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib., Clin Pharmacokinet
    Hilberg et al., 2008, BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy., Cancer Res.
    Papanas et al., 2008, Becaplermin gel in the treatment of diabetic neuropathic foot ulcers., Clin Interv Aging
    Huang et al., 2010, Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant., J. Med. Chem.
    Millward MJ et al., 2006, The multikinase inhibitor midostaurin (PKC412A) lacks activity in metastatic melanoma: a phase IIA clinical and biologic study., Br J Cancer
    Bamborough et al., 2008, Assessment of chemical coverage of kinome space and its implications for kinase drug discovery., J. Med. Chem.
    Choi BK et al., 2013, Sponge-derived acetylenic alcohols, petrosiols, inhibit proliferation and migration of platelet-derived growth factor (PDGF)-induced vascular smooth muscle cells., Bioorg Med Chem
  • BECAPLERMIN   PDGFRB

    Interaction Score: 2.18

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Mechanism of Interaction Platelet-derived growth factor receptor agonist
    Direct Interaction yes
    Trial Name becaplermin,Regranex

    PMIDs:
    18686746


    Sources:
    TdgClinicalTrial ChemblInteractions TEND TTD

  • PETROSIOL A   PDGFRB

    Interaction Score: 1.74

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23415061


    Sources:
    DTC

  • CDP-860   PDGFRB

    Interaction Score: 0.87

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Platelet-derived growth factor receptor beta inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • TELATINIB   PDGFRB

    Interaction Score: 0.58

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Novel drug target Established target
    Trial Name telatinib
    Notes

    PMIDs:
    None found


    Sources:
    TALC MyCancerGenome TdgClinicalTrial ChemblInteractions

  • BAFETINIB   PDGFRB

    Interaction Score: 0.44

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26703895


    Sources:
    CIViC

  • MOTESANIB   PDGFRB

    Interaction Score: 0.44

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Notes
    Novel drug target Established target
    Trial Name motesanib diphosphate, AMG 706

    PMIDs:
    None found


    Sources:
    TALC MyCancerGenome TdgClinicalTrial ChemblInteractions

  • REBASTINIB   PDGFRB

    Interaction Score: 0.35

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26703895


    Sources:
    CIViC

  • X-82   PDGFRB

    Interaction Score: 0.35

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Platelet-derived growth factor receptor inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    MyCancerGenome ChemblInteractions

  • TAK-593   PDGFRB

    Interaction Score: 0.35

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Platelet-derived growth factor receptor inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions TTD

  • JI-101   PDGFRB

    Interaction Score: 0.29

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Platelet-derived growth factor receptor beta inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • XL-820   PDGFRB

    Interaction Score: 0.29

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Platelet-derived growth factor receptor inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions TTD

  • SUNITINIB   PDGFRB

    Interaction Score: 0.29

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Notes
    Trial Name Sutent
    Novel drug target Established target

    PMIDs:
    29760553 16425993 15557593 14753710 12748309 12538485 19248971


    Sources:
    TALC MyCancerGenome TdgClinicalTrial TEND CIViC PharmGKB

  • VATALANIB   PDGFRB

    Interaction Score: 0.27

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Platelet-derived growth factor receptor inhibitor
    Direct Interaction yes
    Notes

    PMIDs:
    None found


    Sources:
    TALC DTC TdgClinicalTrial ChemblInteractions

  • TANDUTINIB   PDGFRB

    Interaction Score: 0.26

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Platelet-derived growth factor receptor beta inhibitor

    PMIDs:
    None found


    Sources:
    DTC MyCancerGenome ChemblInteractions

  • FAMITINIB   PDGFRB

    Interaction Score: 0.25

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Platelet-derived growth factor receptor inhibitor

    PMIDs:
    None found


    Sources:
    ChemblInteractions TTD

  • NINTEDANIB   PDGFRB

    Interaction Score: 0.25

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Notes
    Trial Name BIBF-1120,Vargatef
    Novel drug target Established target

    PMIDs:
    31016670 18559524


    Sources:
    TALC MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial

  • IMATINIB   PDGFRB

    Interaction Score: 0.25

    Interaction Types & Directionality:
    antagonist (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name imatinib mesylate, STI 571,Gleevec, Glivec
    Novel drug target Established target

    PMIDs:
    16960151 32068648 24186319 23835704 15794712 15803362 15887238 15753388 15893416 26703895


    Sources:
    DTC MyCancerGenome TdgClinicalTrial TEND CIViC PharmGKB FDA OncoKB

  • NILOTINIB   PDGFRB

    Interaction Score: 0.24

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    26703895


    Sources:
    CIViC MyCancerGenomeClinicalTrial

  • AXITINIB   PDGFRB

    Interaction Score: 0.22

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Notes
    Trial Name axitinib, AG-013736
    Novel drug target Established target

    PMIDs:
    None found


    Sources:
    TALC MyCancerGenome TdgClinicalTrial

  • CM-082   PDGFRB

    Interaction Score: 0.22

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Platelet-derived growth factor receptor beta inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • ORANTINIB   PDGFRB

    Interaction Score: 0.19

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Platelet-derived growth factor receptor inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    MyCancerGenome ChemblInteractions

  • MASITINIB   PDGFRB

    Interaction Score: 0.19

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name masitinib, AB1010
    Novel drug target Established target
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial ChemblInteractions MyCancerGenomeClinicalTrial

  • ANLOTINIB   PDGFRB

    Interaction Score: 0.17

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Platelet-derived growth factor receptor beta inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • PONATINIB   PDGFRB

    Interaction Score: 0.16

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20513156 26703895


    Sources:
    DTC CIViC

  • PEGPLERANIB SODIUM   PDGFRB

    Interaction Score: 0.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Trial Name E-10030
    Novel drug target Established target

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial

  • CRENOLANIB   PDGFRB

    Interaction Score: 0.15

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Platelet-derived growth factor receptor inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • SORAFENIB   PDGFRB

    Interaction Score: 0.14

    Interaction Types & Directionality:
    antagonist (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name Nexavar
    Novel drug target Established target
    Notes

    PMIDs:
    17619763 16425993 17545544 28362716


    Sources:
    TALC DTC MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial TEND MyCancerGenomeClinicalTrial PharmGKB TTD

  • DASATINIB   PDGFRB

    Interaction Score: 0.14

    Interaction Types & Directionality:
    antagonist (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Platelet-derived growth factor receptor beta inhibitor
    Trial Name dasatinib, BMS-354825,Sprycel

    PMIDs:
    16436588 16497876 20072833 26703895 29133777


    Sources:
    DTC TdgClinicalTrial ChemblInteractions TEND CIViC MyCancerGenomeClinicalTrial

  • AMUVATINIB   PDGFRB

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Trial Name MP-470
    Novel drug target Established target

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial

  • REGORAFENIB   PDGFRB

    Interaction Score: 0.12

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Platelet-derived growth factor receptor inhibitor
    Direct Interaction yes
    Notes

    PMIDs:
    None found


    Sources:
    TALC MyCancerGenome ChemblInteractions MyCancerGenomeClinicalTrial

  • SU-014813   PDGFRB

    Interaction Score: 0.12

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Platelet-derived growth factor receptor inhibitor

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • ROMIPLOSTIM   PDGFRB

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • PAZOPANIB   PDGFRB

    Interaction Score: 0.11

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Notes

    PMIDs:
    17288876


    Sources:
    TALC DTC MyCancerGenome MyCancerGenomeClinicalTrial

  • SUNITINIB MALATE   PDGFRB

    Interaction Score: 0.1

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Platelet-derived growth factor receptor inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • BARASERTIB   PDGFRB

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • NINTEDANIB ESYLATE   PDGFRB

    Interaction Score: 0.1

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Platelet-derived growth factor receptor inhibitor

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • QUIZARTINIB   PDGFRB

    Interaction Score: 0.1

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Platelet-derived growth factor receptor inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • IMATINIB MESYLATE   PDGFRB

    Interaction Score: 0.09

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Platelet-derived growth factor receptor beta inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • PAZOPANIB HYDROCHLORIDE   PDGFRB

    Interaction Score: 0.08

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Platelet-derived growth factor receptor inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • PUQUITINIB   PDGFRB

    Interaction Score: 0.08

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Platelet-derived growth factor receptor beta inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • XL-999   PDGFRB

    Interaction Score: 0.08

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Platelet-derived growth factor receptor inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • FORETINIB   PDGFRB

    Interaction Score: 0.07

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Platelet-derived growth factor receptor inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • LENVATINIB   PDGFRB

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Trial Name E7080
    Novel drug target Established target

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial

  • MK-2461   PDGFRB

    Interaction Score: 0.07

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • MIDOSTAURIN   PDGFRB

    Interaction Score: 0.07

    Interaction Types & Directionality:
    antagonist (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Platelet-derived growth factor receptor inhibitor

    PMIDs:
    16969355


    Sources:
    ChemblInteractions

  • CEDIRANIB   PDGFRB

    Interaction Score: 0.06

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Notes
    Mechanism of Interaction Platelet-derived growth factor receptor inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    TALC DTC ChemblInteractions

  • SORAFENIB TOSYLATE   PDGFRB

    Interaction Score: 0.05

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Platelet-derived growth factor receptor beta inhibitor

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • TG100-801   PDGFRB

    Interaction Score: 0.05

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Platelet-derived growth factor receptor beta inhibitor

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • RABEPRAZOLE SODIUM   PDGFRB

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • CEP-2563   PDGFRB

    Interaction Score: 0.05

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Platelet-derived growth factor receptor beta inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • LINIFANIB   PDGFRB

    Interaction Score: 0.05

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name ABT-869, Linifanib
    Novel drug target Established target
    Mechanism of Interaction Platelet-derived growth factor receptor inhibitor

    PMIDs:
    None found


    Sources:
    DTC MyCancerGenome TdgClinicalTrial ChemblInteractions

  • DORAMAPIMOD   PDGFRB

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DOVITINIB   PDGFRB

    Interaction Score: 0.04

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name dovitinib, TKI-258, CHIR-258
    Novel drug target Established target
    Mechanism of Interaction Platelet-derived growth factor receptor inhibitor

    PMIDs:
    None found


    Sources:
    DTC TdgClinicalTrial ClearityFoundationClinicalTrial ChemblInteractions

  • AZD-1152-HQPA   PDGFRB

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • PD-0166285   PDGFRB

    Interaction Score: 0.03

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Platelet-derived growth factor receptor beta inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    DTC ChemblInteractions

  • ENMD-981693   PDGFRB

    Interaction Score: 0.03

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Platelet-derived growth factor receptor inhibitor

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • CHEMBL406845   PDGFRB

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CHEMBL546797   PDGFRB

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • AST-487   PDGFRB

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • HESPERADIN   PDGFRB

    Interaction Score: 0.02

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    19035792


    Sources:
    DTC

  • SNS-314   PDGFRB

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • RG-1530   PDGFRB

    Interaction Score: 0.02

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Platelet-derived growth factor receptor beta inhibitor

    PMIDs:
    None found


    Sources:
    DTC ChemblInteractions

  • OSI-632   PDGFRB

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • ILORASERTIB   PDGFRB

    Interaction Score: 0.02

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Platelet-derived growth factor receptor inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    DTC ChemblInteractions

  • VANDETANIB   PDGFRB

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • SOTRASTAURIN   PDGFRB

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • TOZASERTIB   PDGFRB

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • R-406   PDGFRB

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • TAE-684   PDGFRB

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • PF-00562271   PDGFRB

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CENISERTIB   PDGFRB

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • Ensembl: ENSG00000113721

    • Version: 101_38

    Alternate Names:
    PDGFRB Ensembl Gene Name

    Gene Info:
    Gene Biotype PROTEIN_CODING

    Publications:

  • TEND: P09619

    • Version: 01-August-2011

    Alternate Names:
    ENSG00000113721 Ensembl Gene Id
    PDGFRB Gene Symbol
    PGFRB_HUMAN Uniprot Id

    Gene Info:
    Target Subclass KInase
    Target Main Class Receptors
    Transmembrane Helix Count 1

    Publications:

  • HopkinsGroom: P09619

    • Version: 11-September-2012

    Alternate Names:
    PLATELET-DERIVED GROWTH FACTOR RECEPTOR BETA Uniprot Protein Name
    P09619 Uniprot Accession
    5159 Entrez Gene Id

    Gene Info:
    Interpro Short Name Ser-Thr/Tyr_kinase_cat_dom
    Uniprot Evidence 1: Evidence at protein level
    Human Readable Name KINASE

    Gene Categories:
    KINASE, DRUGGABLE GENOME

    Publications:

  • RussLampel: ENSG00000113721

    • Version: 26-July-2011

    Alternate Names:
    ENSG00000113721 Ensembl Gene Id
    BETA PLATELET-DERIVED GROWTH FACTOR RECEPTOR PRECURSOR (EC 2.7.1.112) (PDGF-R-BETA) (CD140B ANTIGEN). [SOURCE:UNIPROT/SWISSPROT;ACC:P09619] Description
    PDGFRB Display Id

    Gene Info:
    Human Readable Name DRUGGABLE GENOME

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • TdgClinicalTrial: P09619

    • Version: January-2014

    Alternate Names:
    PDGFRB Gene Symbol

    Gene Info:
    Target Class Receptors
    Target Subclass EC:2.7.10.1

    Publications:

  • PharmGKB: PDGFRB

    • Version: 18-August-2020

    Alternate Names:
    PA33148 PharmGKB ID

    Gene Info:

    Publications:
    Quek R et al., 2009, Gastrointestinal stromal tumor: a clinical overview., Hematol Oncol Clin North Am
    Mendel et al., 2003, In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship., Clin. Cancer Res.
    Gong L et al., 2017, PharmGKB summary: sorafenib pathways., Pharmacogenet Genomics

  • CIViC: PDGFRB

    • Version: 14-September-2020

    Alternate Names:
    5159 Entrez Gene ID
    4176 CIViC Gene ID

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:
    Sakurai Y et al., 2020, B-Cell Precursor-Acute Lymphoblastic Leukemia With EBF1-PDGFRB Fusion Treated With Hematopoietic Stem Cell Transplantation and Imatinib: A Case Report and Literature Review., J Pediatr Hematol Oncol
    Weston et al., 2013, Tyrosine kinase inhibitor therapy induces remission in a patient with refractory EBF1-PDGFRB-positive acute lymphoblastic leukemia., J. Clin. Oncol.
    Ishibashi T et al., 2016, Ph-like ALL-related novel fusion kinase ATF7IP-PDGFRB exhibits high sensitivity to tyrosine kinase inhibitors in murine cells., Exp Hematol

  • DTC: PDGFRB

    • Version: 02-September-2020

    Alternate Names:

    Gene Info:

    Publications:
    Bamborough et al., 2008, Assessment of chemical coverage of kinome space and its implications for kinase drug discovery., J. Med. Chem.
    Huang et al., 2010, Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant., J. Med. Chem.
    Choi BK et al., 2013, Sponge-derived acetylenic alcohols, petrosiols, inhibit proliferation and migration of platelet-derived growth factor (PDGF)-induced vascular smooth muscle cells., Bioorg Med Chem

  • HingoraniCasas: ENSG00000113721

    • Version: 31-May-2017

    Alternate Names:
    ENSG00000113721 Gene Symbol
    PDGFRB Ensembl Id

    Gene Info:

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • TALC: PDGFRB

    • Version: 12-May-2016

    Alternate Names:
    PDGFRB Gene Symbol

    Gene Info:

    Publications:

  • MyCancerGenome: PDGFRB

    • Version: 20-Jun-2017

    Alternate Names:
    5159 Entrez Gene Id
    PDGFRB MyCancerGenome Gene Symbol
    PDGFR-beta MyCancerGenome Reported Gene Name

    Gene Info:

    Publications:

  • ChemblInteractions: PDGFR

    • Version: chembl_23

    Alternate Names:
    PDGFR1 GENE_SYMBOL
    PDGFRB GENE_SYMBOL
    Platelet-derived growth factor receptor beta UNIPROT

    Gene Info:

    Publications:

  • OncoKB: PDGFRB

    • Version: 23-July-2020

    Alternate Names:
    5159 OncoKB Entrez Id
    PDGFR1 OncoKB Gene Synonym
    KOGS OncoKB Gene Synonym

    Gene Info:

    Publications:

  • GO: PDGFRB

    • Version: 01-February-2022

    Alternate Names:
    PDGFR GO Gene Synonym
    PDGFR1 GO Gene Synonym

    Gene Info:

    Gene Categories:
    CELL SURFACE, TYROSINE KINASE

    Publications:

  • Tempus: PDGFRB

    • Version: 11-November-2018

    Alternate Names:
    PDGFRB Gene Symbol

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • dGene: PDGFRB

    • Version: 27-Jun-2013

    Alternate Names:
    5159 Gene ID
    CD140B dGene Synonym
    JTK12 dGene Synonym

    Gene Info:

    Gene Categories:
    KINASE, TYROSINE KINASE

    Publications:

  • TTD: Platelet-derived growth factor receptor beta

    • Version: 2020.06.01

    Alternate Names:
    PDGFRB TTD Gene Abbreviation
    T59102 TTD Target ID

    Gene Info:

    Publications:

  • Pharos: PDGFRB

    • Version: 01-February-2022

    Alternate Names:
    Platelet-derived growth factor receptor beta Gene Name
    P09619 UniProt ID

    Gene Info:

    Gene Categories:
    KINASE

    Publications:

  • ClearityFoundationClinicalTrial: PDGFRB

    • Version: 15-June-2013

    Alternate Names:

    Gene Info:

    Publications:

  • MskImpact: PDGFRB

    • Version: May-2015

    Alternate Names:

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • MyCancerGenomeClinicalTrial: PDGFRB

    • Version: 30-February-2014

    Alternate Names:

    Gene Info:

    Publications:

  • FoundationOneGenes: PDGFRB

    • Version: 03-September-2020

    Alternate Names:

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • CarisMolecularIntelligence: PDGFRB

    • Version: 04-September-2020

    Alternate Names:

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • FDA: PDGFRB

    • Version: 04-September-2020

    Alternate Names:

    Gene Info:

    Publications:

  • Oncomine: PDGFRB

    • Version: v3

    Alternate Names:

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21